プログラフカプセル０．５ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00864 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 50 |
| 日本商品名（例） | タクロリムスカプセル０．５ｍｇ「サンド」, タクロリムスカプセル０．５ｍｇ「ニプロ」, タクロリムスカプセル０．５ｍｇ「ＪＧ」 |
承認適応症（KEGG）
臓器移植における拒絶反応、移植片対宿主病、重症筋無力症、関節リウマチ、ループス腎炎、活動期潰瘍性大腸炎、多発性筋炎・皮膚筋炎、アトピー性皮膚炎
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | atopic eczema | 99% | DL |
| 2 | seborrheic dermatitis | 99% | DL |
| 3 | parapsoriasis | 99% | DL |
| 4 | dermatitis, atopic | 99% | DL |
| 5 | dermatitis | 99% | DL |
| 6 | acute lichenoid pityriasis | 98% | DL |
| 7 | acrodermatitis chronica atrophicans | 98% | DL |
| 8 | rheumatoid arthritis | 98% | DL |
| 9 | acne keloid | 98% | DL |
| 10 | psoriasis | 98% | DL |
| 11 | neonatal dermatomyositis | 98% | DL |
| 12 | exanthem (disease) | 98% | DL |
| 13 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 98% | DL |
| 14 | amyopathic dermatomyositis | 98% | DL |
| 15 | bronchitis | 98% | DL |
| 16 | pityriasis lichenoides | 98% | DL |
| 17 | hydroa vacciniforme, familial | 98% | DL |
| 18 | brachydactyly-syndactyly syndrome | 97% | DL |
| 19 | pustulosis palmaris et plantaris | 97% | DL |
| 20 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 97% | DL |
| 21 | Crohn's colitis | 96% | DL |
| 22 | psoriasis 14, pustular | 96% | DL |
| 23 | pemphigus | 95% | DL |
| 24 | 2-hydroxyethyl methacrylate sensitization | 95% | DL |
| 25 | polyp of vocal cord | 95% | DL |
| 26 | epulis | 95% | DL |
| 27 | polyp of middle ear | 95% | DL |
| 28 | fibroepithelial polyp | 95% | DL |
| 29 | polyp of frontal sinus | 95% | DL |
| 30 | polyp of ureter | 95% | DL |
| 31 | polyp of vulva | 95% | DL |
| 32 | neoplastic polyp | 95% | DL |
| 33 | polyp of external auditory canal | 95% | DL |
| 34 | uterine polyp | 95% | DL |
| 35 | pemphigus vegetans | 95% | DL |
| 36 | inflammatory bowel disease | 93% | DL |
| 37 | lipoid nephrosis | 93% | DL |
| 38 | alopecia universalis onychodystrophy vitiligo | 93% | DL |
| 39 | candidiasis, familial | 92% | DL |
| 40 | Crohn disease of the esophagus | 91% | DL |
| 41 | seborrheic keratosis | 91% | DL |
| 42 | persistent polyclonal B-cell lymphocytosis | 91% | DL |
| 43 | granulomatous disease with defect in neutrophil chemotaxis | 91% | DL |
| 44 | anus disease | 91% | DL |
| 45 | folliculotropic mycosis fungoides | 91% | DL |
| 46 | vulvar inverted follicular keratosis | 91% | DL |
| 47 | functional neutrophil defect | 91% | DL |
| 48 | granulomatous disease, chronic, autosomal recessive, 5 | 91% | DL |
| 49 | BENTA disease | 91% | DL |
| 50 | severe combined immunodeficiency due to CARD11 deficiency | 90% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。